Abstract

 CADTH recommends that Vabysmo be reimbursed by public drug plans for the treatment of diabetic macular edema (DME) if certain conditions are met.
 Vabysmo should be covered to treat patients with DME provided that it is covered for a similar patient population and in a similar way to other anti–vascular endothelial growth factor (VEGF) drugs currently reimbursed by public drug plans for the treatment of adult patients with DME.
 Vabysmo should only be reimbursed if prescribed by an ophthalmologist with experience managing DME and if the cost of Vabysmo is not more than the least costly anti-VEGF drug covered by the public drug plans for the treatment of DME.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
